Stock Ratings / Health Care / ABSI / financials

OABI (44) NRC (67) ICLR (71) CRL (63) ⌘ Pro Terminal →

Absci Corporation (ABSI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$11.13 -8.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.95

Absci Corporation (ABSI) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.08B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABSI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Absci Corporation (NASDAQ: ABSI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $11.13 (-8.02% 1D, market cap $2.08B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABSI ranks #399 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABSI compare to OABI and NRC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ABSI carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OABI (OmniAb Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $760.4M) and NRC (NRC Health) posts a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABSI?

▼

Per ABSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672688), Absci Corporation generated $0 in revenue (-100.0% YoY), -$115.2M in net income, and -$94.0M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.95 (-1.63%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABSI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY ABSI SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (38% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$9.67-11.7% Next Q

Q2 (-2Q)

Grade D$8.54+10.7% Next Q

Q3 (-1Q)

Grade D$9.45+17.8% Next Q

Current

Grade D$11.13-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABSI currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.56) and Max Pain ($11.69) forces dealer call-delta covering toward $13.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ABSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ABSI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $5.7M

FY24

Rev $4.5M

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-3%	-$115.2M	-$94.0M	-45%
FY 2024	$4.5M	52%	-80%	-$103.1M	-$72.8M	-45%
FY 2023	$5.7M	52%	-80%	-$110.6M	-$64.6M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABSI)

✓Walkthrough of ABSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +98.04%▲ ASCENDING CHANNEL

2026-11-02O $11.88H $12.10L $11.13C $11.13VOL 4.34M

RES: $12.99SUP: $8.40SMA50: $9.56SMA200: $6.53

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABSI Butterfly Map → + Track ABSI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ABSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABSI)

Health Care Rank #399 of 1016 ⚔️ OABI vs ABSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABSI vs. OABI, NRC, ICLR, CRL)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Absci Corporation (ABSI) ranks #399 by composite RQD confidence (45/100, grade D) and #255 by equity capitalization ($2.08B). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with ABSI at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABSI ACTIVE Absci Corporation	D	45/100	—	—	-35.0%	-8.02%	$2.08B	Benchmark Subject
OABI OmniAb Inc.	D	44/100	—	—	-22.6%	-2.29%	$760.4M	/oabi-vs-absi →
NRC NRC Health	C+	67/100	44.8x	—	21.0%	+1.45%	$519.6M	/nrc-vs-absi →
ICLR ICON plc	B-	71/100	71.9x	—	3.1%	-1.91%	$16.50B	/iclr-vs-absi →
CRL Charles River Laboratories International Inc.	C	63/100	—	—	0.4%	-4.44%	$17.95B	/crl-vs-absi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001672688

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Absci Corporation (ABSI) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $4.5M , and -100.0% cumulative change since FY2023) , GAAP net income of -$115.2M, operating cash flow of -$92.9M, and free cash flow of -$94.0M (-29.2% YoY). On the balance sheet, ABSI closed FY2025 with $216.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$115.2M	-$92.9M	-$94.0M	$216.3M	—
FY2024 (FY)	2024-12-31	$4.5M	-$103.1M	-$72.4M	-$72.8M	$213.6M	—
FY2023 (FY)	2023-12-31	$5.7M	-$110.6M	-$64.6M	-$64.6M	—	—

3. ABSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ABSI compare to OABI and NRC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ABSI?

Where is ABSI trading relative to its 50-day, 200-day, and 52-week technical levels?

ABSI last traded at $11.13 (-8.02% on volume of 4,566,029 shares), positioning the stock +16.42% above its 50-day simple moving average ($9.56) and +70.44% above its 200-day simple moving average ($6.53). Across its 52-week range of $2.24 to $12.55, ABSI sits at the 86.2% percentile with a 14-day RSI of 62.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($9.74 to $12.52).

ABSI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Absci Corporation (ABSI)?

In FY 2025 (10-K), ABSI converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ABSI RQD Cockpit ABSI 12M Forecast ABSI Earnings & Move ABSI Dividends & DRIP ABSI Insiders & 13F ABSI Whale Options ABSI Profit Sankey ABSI News & Why

Sector Peer Dials

Charles River Laboratories International Inc.

63 /100

MEDP B+

Medpace Holdings Inc.

ABSI Core Snapshot

Market Cap $2.08B

Trailing / Fwd P/E — / —

Gross Profit Margin —

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield -4.53%

12M Base Price Target $10.48

FREE TRADER TOOLS

Own ABSI Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With ABSI → 🏆 Trade ABSI in $100K Prop Arena →

ABSI Wire

Why It Moved →

Direct Company Event Yahoo! Finance Canada • 11h ago

Absci Corporation (ABSI) Stock Price, News, Quote & History

Direct Company Event Yahoo Finance • 14h ago

Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop

Direct Company Event TradingView • 17h ago

Absci Corporation Estimates – NASDAQ:ABSI

Direct Company Event MarketBeat • 20h ago

Absci (NASDAQ:ABSI) Stock Jumps 13.2% - Still a Buy?

Direct Company Event MarketBeat • 23h ago

Absci (NASDAQ:ABSI) Shares Down 5.5% - Here's Why

ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ABSI — Absci Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:26:47Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 45 / D, labeled "Roarable Sell — Underperform / Distribution Warning," per the Roarable RQD rating.

Fundamental Cash Engine (6 / 20): Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -4.53%. For a prospective investor, the weakness here means the business is not currently generating cash returns on invested capital, so valuation support must come from elsewhere.
Whale 13F Flow (17 / 20): Per the Roarable RQD rating, this is the strongest pillar, reflecting institutional accumulation and options positioning. This is a meaningful upside driver in the rating, though it describes positioning rather than business earnings power.
Insider Conviction (3 / 20): Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow and scores very low. A prospective investor should note the weak insider-conviction signal as a caution.
Macro Regime Fit (9 / 20): Per the Roarable RQD rating, beta is 1.0 with a sector sensitivity read. This implies the stock moves roughly in line with the market, with limited defensive character from this pillar.
Forensic Balance Sheet (10 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These readings are mixed-to-weak and present a valuation tradeoff: the reported figures do not show strong financial health.

Overall, the rating's sell label rests mainly on negative cash generation and a weak forensic profile, partly offset by institutional positioning. This is an analytical framing, not personalized advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-120.3M	$-115.2M	N/A	$-94.0M	$20.0M	N/A
FY 2024	$4.5M	$-108.9M	$-103.1M	N/A	$-72.8M	$41.2M	N/A
FY 2023	$5.7M	$-115.5M	$-110.6M	N/A	$-64.6M	N/A	N/A

Per the SEC financials, revenue declined from $5.7M (FY 2023) to $4.5M (FY 2024) to $0.0M (FY 2025), while operating losses remained large in each period. Per the market data, gross, operating, and net margins are each reported as 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the Roarable RQD rating, Debt/Equity is 0.5; the debt figure in the SEC financials is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items relate to ABSI, sourced from Yahoo! Finance Canada, Yahoo Finance, TradingView, MarketBeat (two items), and a siam.in-sourced item. Headlines include a stock-price and news-quote page, a book-value valuation piece tagged as a catalyst, an estimates page, two MarketBeat items reporting a 13.2% jump and a 5.5% decline, and a report of a 13.47% slide to $10.47 toward key support. Per the feed, these items carry mixed light signals (YELLOW and GREEN). Risk watch items include the reported slide and the book-value framing. The Butterfly Supply-Chain Graph reports no proprietary signals.

Open Questions

What is the company's product and revenue model, given that FY 2025 revenue is reported as $0.0M?
What is the FY 2025 debt figure and the FY 2023 cash balance, both reported as N/A?
What are the TTM EPS and P/E ratios, which the source data does not provide?
Who are the institutional and insider holders behind the whale 13F and insider pillar scores?
What drove the reported 13.47% slide and the 13.2% jump in the news feed?

ABSI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Absci Corporation (ABSI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABSI Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 11h ago

Absci Corporation (ABSI) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 14h ago

Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop

Yahoo Finance report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 17h ago

Absci Corporation Estimates – NASDAQ:ABSI

TradingView report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 20h ago

Absci (NASDAQ:ABSI) Stock Jumps 13.2% - Still a Buy?

MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 23h ago

Absci (NASDAQ:ABSI) Shares Down 5.5% - Here's Why

MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Absci Corporation (ABSI) Slides 13.47% to $10.47 as Shares Retreat Toward Key Support - Call Resistance

https://www.siam.in/ report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Absci Corporation (NASDAQ:ABSI) Stock Has Average Target Price of $13.71

MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Absci Corporation (NASDAQ:ABSI) Stock Rated "Moderate Buy" by Sell-Side Analysts

MarketBeat report covering Absci Corporation (ABSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABSI Bull vs. Bear Conversation Board — What's Your Call at $11.13?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABSI 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $10.65 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ABSI (D • RQD 45/100) a Buy at $12.10?

Welcome to the ABSI (Absci Corporation) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.68 (-20.0%)

Spot @ $12.10

Pump the brakes on ABSI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ABSI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Absci Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $15.49 (+28.0%)

Spot @ $12.10

ABSI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ABSI, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $12.10 (52-wk range $2.24 - $12.55), any beat on forward guidance forces shorts and underweight funds to chase.